A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy

被引:121
作者
Hamberg, A-K [1 ]
Dahl, M-L
Barban, M.
Scordo, M. G.
Wadelius, M.
Pengo, V.
Padrini, R.
Jonsson, E. N.
机构
[1] Uppsala Univ, Dept Med Sci, Uppsala, Sweden
[2] Univ Padua, Dept Clin & Expt Med, Padua, Italy
[3] Uppsala Univ, Dept Pharmaceut Biosci, Uppsala, Sweden
关键词
D O I
10.1038/sj.clpt.6100084
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this study was to characterize the relationship between warfarin concentrations and international normalized ratio (INR) response and to identify predictors important for dose individualization. S- and R-warfarin concentrations, INR, and CYP2C9 and VKORC1 genotypes from 150 patients were used to develop a population pharmacokinetic/pharmacodynamic model in NONMEM. The anticoagulant response was best described by an inhibitory E-MAX model, with S- warfarin concentration as the only exposure predictor for response. Delay between exposure and response was accounted for by a transit compartment model with two parallel transit compartment chains. CYP2C9 genotype and age were identified as predictors for S- warfarin clearance, and VKORC1 genotype as a predictor for warfarin sensitivity. Predicted INR curves indicate important steady-state differences between patients with different sets of covariates; differences that cannot be foreseen from early INR assessments alone. It is important to account for CYP2C9 and VKORC1 genotypes and age to improve a priori and a posteriori individualization of warfarin therapy.
引用
收藏
页码:529 / 538
页数:10
相关论文
共 24 条
  • [1] Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
    Aithal, GP
    Day, CP
    Kesteven, PJL
    Daly, AK
    [J]. LANCET, 1999, 353 (9154) : 717 - 719
  • [2] BEAL SL, 1994, NONMEM USERS GUIDE N
  • [3] BRECKENRIDGE A, 1974, CLIN PHARMACOL THER, V15, P424
  • [4] Gabrielsson J., 2001, Pharmacokinetic and pharmacodynamic data analysis: concepts and applications
  • [5] The influence of sequence variations in factor VII, γ-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement
    Herman, Darja
    Peternel, Polona
    Stegnar, Mojca
    Breskvar, Katja
    Dolzan, Vita
    [J]. THROMBOSIS AND HAEMOSTASIS, 2006, 95 (05) : 782 - 787
  • [6] MECHANISM OF ACTION, CLINICAL EFFECTIVENESS, AND OPTIMAL THERAPEUTIC RANGE
    HIRSH, J
    DALEN, JE
    DEYKIN, D
    POLLER, L
    BUSSEY, H
    [J]. CHEST, 1995, 108 (04) : S231 - S246
  • [7] Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin
    Hylek, EM
    Regan, S
    Go, AS
    Hughes, RA
    Singer, DE
    Skates, SJ
    [J]. ANNALS OF INTERNAL MEDICINE, 2001, 135 (06) : 393 - 400
  • [8] Jonsson EN, 1999, COMPUT METH PROG BIO, V58, P51, DOI 10.1016/S0169-2607(98)00067-4
  • [9] A rational approach for selection of optimal covariate-based dosing strategies
    Jönsson, S
    Karlsson, MO
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (01) : 7 - 19
  • [10] PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM
    Lindbom, L
    Pihlgren, P
    Jonsson, N
    [J]. COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, 2005, 79 (03) : 241 - 257